2seventy bio (TSVT) Stock Forecast, Price Target & Predictions
TSVT Stock Forecast
2seventy bio stock forecast is as follows: an average price target of $2.00 (represents a -36.71% downside from TSVT’s last price of $3.16) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TSVT Price Target
The average price target for 2seventy bio (TSVT) is $2.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential -36.71% downside from TSVT's last price of $3.16.
TSVT Analyst Ratings
According to 7 Wall Street analysts, 2seventy bio's rating consensus is 'Buy'. The analyst rating breakdown for TSVT stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 1 'Hold' (14.29%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
2seventy bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 06, 2024 | Salveen Richter | Goldman Sachs | - | - | -56.14% | -36.71% |
| May 02, 2022 | Goldman Sachs | - | - | 93.16% | 722.78% |
The latest 2seventy bio stock forecast, released on Jun 06, 2024 by Salveen Richter from Goldman Sachs, set a price target of $2.00, which represents a -56.14% decrease from the stock price at the time of the forecast ($4.56), and a -36.71% decrease from TSVT last price ($3.16).
2seventy bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $3.16 | $3.16 | $3.16 |
| Upside/Downside | -100.00% | -100.00% | -36.71% |
In the current month, the average price target of 2seventy bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 2seventy bio's last price of $3.16. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 12, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Jun 06, 2024 | Goldman Sachs | Buy | Sell | Downgrade |
| Apr 07, 2024 | Citigroup | Buy | Buy | Hold |
| Jan 31, 2024 | Leerink Partners | Outperform | Upgrade | |
| Sep 13, 2023 | Guggenheim | Neutral | Downgrade | |
| Mar 17, 2023 | Wedbush | Outperform | Outperform | Hold |
| Jan 10, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| May 02, 2022 | Goldman Sachs | Buy | Initialise | |
| Apr 26, 2022 | Zacks Investment Research | Buy | Upgrade |
2seventy bio's last stock rating was published by Goldman Sachs on Nov 12, 2024. The company gave TSVT a "Sell" rating, the same as its previous rate.
2seventy bio Financial Forecast
2seventy bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $12.03M | - | $41.62M | $56.18M | $13.41M | $13.48M | $8.43M | $16.03K | $19.26M |
| Avg Forecast | $22.00M | $16.96M | $16.55M | $17.24M | $17.88M | $16.18M | $11.08M | $14.92M | $14.71M | $31.18M | $36.84M | $21.25M | $15.27M | $12.37M | $16.52M | $19.73M | $12.92M | $8.52M |
| High Forecast | $23.81M | $18.35M | $17.91M | $18.66M | $18.99M | $17.51M | $11.08M | $14.92M | $23.72M | $33.74M | $39.87M | $22.99M | $16.53M | $12.37M | $16.52M | $19.73M | $12.92M | $8.52M |
| Low Forecast | $20.19M | $15.56M | $15.19M | $15.83M | $16.76M | $14.85M | $11.08M | $14.92M | $7.72M | $28.62M | $33.82M | $19.51M | $14.02M | $12.37M | $16.52M | $19.73M | $12.92M | $8.52M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.39% | - | 1.96% | 3.68% | 1.08% | 0.82% | 0.43% | 0.00% | 2.26% |
2seventy bio's average Quarter revenue forecast for Dec 23 based on 5 analysts is $14.71M, with a low forecast of $7.72M, and a high forecast of $23.72M. TSVT's average Quarter revenue forecast represents a 22.20% increase compared to the company's last Quarter revenue of $12.03M (Sep 23).
2seventy bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-33.76M | - | $-49.31M | $-24.79M | $-65.89M | $-73.50M | $-86.96M | $11.62M | $-55.33M |
| Avg Forecast | $-19.93M | $-15.36M | $-14.99M | $-15.62M | $-16.20M | $-14.66M | $-10.04M | $-13.52M | $-13.32M | $-28.24M | $-33.38M | $-19.25M | $-13.84M | $-11.02M | $-14.73M | $-17.59M | $-11.52M | $-7.59M |
| High Forecast | $-18.29M | $-14.10M | $-13.76M | $-14.34M | $-15.18M | $-13.45M | $-10.04M | $-13.52M | $-6.99M | $-25.93M | $-30.64M | $-17.67M | $-12.70M | $-11.02M | $-14.73M | $-17.59M | $-11.52M | $-7.59M |
| Low Forecast | $-21.57M | $-16.62M | $-16.22M | $-16.90M | $-17.21M | $-15.86M | $-10.04M | $-13.52M | $-21.49M | $-30.56M | $-36.12M | $-20.83M | $-14.97M | $-11.02M | $-14.73M | $-17.59M | $-11.52M | $-7.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.20% | - | 2.56% | 1.79% | 5.98% | 4.99% | 4.94% | -1.01% | 7.29% |
3 analysts predict TSVT's average Quarter EBITDA for Mar 22 to be $-17.59M, with a high of $-17.59M and a low of $-17.59M. This is -251.32% lower than 2seventy bio's previous annual EBITDA (Dec 21) of $11.62M.
2seventy bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $-71.64M | - | $-42.48M | $-23.14M | $-67.44M | $-77.42M | $-80.93M | $-60.97K | $-60.00M |
| Avg Forecast | $4.18M | $-1.92M | $-3.48M | $-5.40M | $-5.60M | $-10.09M | $-34.80M | $-38.99M | $-54.10M | $-60.05M | $-53.91M | $-65.63M | $-81.31M | $-97.21M | $-118.27M | $-115.80M | $-150.40M | $-136.98M |
| High Forecast | $4.63M | $-1.71M | $-3.11M | $-4.82M | $11.20M | $-9.02M | $-31.08M | $-34.83M | $-41.24M | $-53.64M | $-48.15M | $-58.62M | $-72.63M | $-97.21M | $-118.27M | $-115.80M | $-150.40M | $-136.98M |
| Low Forecast | $3.73M | $-2.12M | $-3.86M | $-5.98M | $-19.60M | $-11.17M | $-38.51M | $-43.15M | $-60.75M | $-66.46M | $-59.66M | $-72.63M | $-89.98M | $-97.21M | $-118.27M | $-115.80M | $-150.40M | $-136.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.19% | - | 0.65% | 0.28% | 0.69% | 0.65% | 0.70% | 0.00% | 0.44% |
2seventy bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TSVT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
2seventy bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $13.00M | - | $20.72M | $18.70M | $19.61M | $17.28M | $23.86M | $24.48K | $23.00M |
| Avg Forecast | $24.13M | $18.60M | $18.15M | $18.91M | $19.61M | $17.74M | $12.15M | $16.36M | $16.13M | $34.20M | $40.41M | $23.31M | $16.75M | $13.56M | $18.13M | $21.64M | $14.17M | $9.34M |
| High Forecast | $26.11M | $20.12M | $19.64M | $20.47M | $20.83M | $19.20M | $12.15M | $16.36M | $26.02M | $37.00M | $43.73M | $25.22M | $18.13M | $13.56M | $18.13M | $21.64M | $14.17M | $9.34M |
| Low Forecast | $22.15M | $17.07M | $16.66M | $17.36M | $18.38M | $16.29M | $12.15M | $16.36M | $8.47M | $31.39M | $37.10M | $21.39M | $15.38M | $13.56M | $18.13M | $21.64M | $14.17M | $9.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.38% | - | 0.89% | 1.12% | 1.45% | 0.95% | 1.10% | 0.00% | 2.46% |
2seventy bio's average Quarter SG&A projection for Dec 23 is $16.13M, based on 5 Wall Street analysts, with a range of $8.47M to $26.02M. The forecast indicates a 24.04% rise compared to TSVT last annual SG&A of $13.00M (Sep 23).
2seventy bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.40 | - | $-0.98 | $-649.41 | $-1.75 | $-2.02 | $-3.03 | $-0.00 | $-2.58 |
| Avg Forecast | $0.08 | $-0.04 | $-0.07 | $-0.10 | $-0.11 | $-0.19 | $-0.67 | $-0.75 | $-1.04 | $-1.15 | $-1.03 | $-1.26 | $-1.56 | $-1.77 | $-2.15 | $-2.10 | $-2.73 | $-2.49 |
| High Forecast | $0.09 | $-0.03 | $-0.06 | $-0.09 | $0.21 | $-0.17 | $-0.59 | $-0.67 | $-0.79 | $-1.03 | $-0.92 | $-1.12 | $-1.39 | $-1.77 | $-2.15 | $-2.10 | $-2.73 | $-2.49 |
| Low Forecast | $0.07 | $-0.04 | $-0.07 | $-0.11 | $-0.38 | $-0.21 | $-0.74 | $-0.83 | $-1.16 | $-1.27 | $-1.14 | $-1.39 | $-1.72 | $-1.77 | $-2.15 | $-2.10 | $-2.73 | $-2.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.22% | - | 0.78% | 417.44% | 0.99% | 0.94% | 1.44% | 0.00% | 1.03% |
According to undefined Wall Street analysts, 2seventy bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TSVT previous annual EPS of $NaN (undefined).
2seventy bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals | - | - | 587.42% | Buy |
| INZY | Inozyme Pharma | - | - | 445.35% | Buy |
| RLAY | Relay Therapeutics | - | - | 318.10% | Buy |
| PLRX | Pliant Therapeutics | - | - | 209.03% | Buy |
| DAWN | Day One Biopharmaceuticals | - | - | 190.85% | Buy |
| PHAT | Phathom Pharmaceuticals | - | - | 173.33% | Buy |
| STOK | Stoke Therapeutics | - | - | 171.52% | Buy |
| CGEM | Cullinan Oncology | - | - | 157.77% | Buy |
| IOVA | Iovance Biotherapeutics | - | - | 154.85% | Buy |
| RCUS | Arcus Biosciences | - | - | 131.09% | Buy |
| KZR | Kezar Life Sciences | - | - | 129.66% | Buy |
| SNDX | Syndax Pharmaceuticals | - | - | 119.87% | Buy |
| REPL | Replimune Group | - | - | 119.00% | Buy |
| ASND | Ascendis Pharma | - | - | 55.10% | Buy |
| SRPT | Sarepta Therapeutics | - | - | 53.00% | Buy |
| MRSN | Mersana Therapeutics | - | - | 51.52% | Buy |
| DICE | DICE Therapeutics | - | - | 26.18% | Buy |
| CRNX | Crinetics Pharmaceuticals | - | - | 22.99% | Buy |
| PTGX | Protagonist Therapeutics | - | - | 20.05% | Buy |
| KDNY | Chinook Therapeutics | - | - | -25.72% | Buy |
| TSVT | 2seventy bio | - | - | -36.71% | Buy |